CY1814A - Oral formulation of buspirone and salts thereof - Google Patents

Oral formulation of buspirone and salts thereof

Info

Publication number
CY1814A
CY1814A CY181495A CY181495A CY1814A CY 1814 A CY1814 A CY 1814A CY 181495 A CY181495 A CY 181495A CY 181495 A CY181495 A CY 181495A CY 1814 A CY1814 A CY 1814A
Authority
CY
Cyprus
Prior art keywords
buspirone
salts
oral formulation
bioavailability
increase
Prior art date
Application number
CY181495A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CY1814A publication Critical patent/CY1814A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Plural Heterocyclic Compounds (AREA)
CY181495A 1987-10-22 1995-10-20 Oral formulation of buspirone and salts thereof CY1814A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8704097A SE8704097D0 (sv) 1987-10-22 1987-10-22 Oral formulation of buspirone and salts thereof

Publications (1)

Publication Number Publication Date
CY1814A true CY1814A (en) 1995-10-20

Family

ID=20369959

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181495A CY1814A (en) 1987-10-22 1995-10-20 Oral formulation of buspirone and salts thereof

Country Status (21)

Country Link
EP (1) EP0313535B1 (ja)
JP (1) JP2674170B2 (ja)
KR (1) KR970004906B1 (ja)
AT (1) ATE108997T1 (ja)
AU (1) AU604585B2 (ja)
CY (1) CY1814A (ja)
DE (1) DE3850844T2 (ja)
DK (1) DK294489A (ja)
ES (1) ES2056955T3 (ja)
FI (1) FI100303B (ja)
HK (1) HK21295A (ja)
HU (1) HU204998B (ja)
IE (1) IE64705B1 (ja)
IL (1) IL88020A (ja)
NO (1) NO892512D0 (ja)
NZ (1) NZ226604A (ja)
PT (1) PT88820B (ja)
SE (1) SE8704097D0 (ja)
WO (1) WO1989003676A1 (ja)
YU (1) YU47903B (ja)
ZA (1) ZA887624B (ja)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU208495B (en) * 1990-06-27 1993-11-29 Alkaloida Vegyeszeti Gyar Process for producing retarde pharmaceutical compositions
US5484788A (en) * 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
US5631017A (en) * 1993-03-26 1997-05-20 Beth Israel Deaconess Medical Center, Inc. Topical application of buspirone for treatment of pathological conditions associated with immune responses
DE4341156C2 (de) * 1993-12-02 1997-11-13 Wacker Chemie Gmbh Verwendung von in Wasser redispergierbaren Kunststoffdispersionspulvern als Arzneimittelträger
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
US5637314A (en) * 1995-06-07 1997-06-10 Beth Israel Deaconess Medical Center, Inc. Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
PL192273B1 (pl) * 1997-09-25 2006-09-29 Bayer Ag Preparat środka leczniczego w postaci pastylki o kontrolowanej dyfuzji lub w postaci układu matrycowego, o kontrolowanym uwalnianiu substancji czynnej
US6268368B1 (en) * 2000-03-01 2001-07-31 American Pharmaceuticals International Anionic exchange polymer complexes of buspirone
CN117257747B (zh) * 2023-11-21 2024-01-30 泊诺(天津)创新医药研究有限公司 一种盐酸丁螺环酮片及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759371A (fr) * 1969-11-24 1971-05-24 Bristol Myers Co Azaspirodecanediones heterocycliques et procedes pour leur preparation
SE353229B (ja) * 1970-06-04 1973-01-29 Haessle Ab
US4182703A (en) * 1978-01-09 1980-01-08 Eastman Kodak Company Biheterocyclic ultraviolet stabilizers and their use in organic compositions
US4182763A (en) * 1978-05-22 1980-01-08 Mead Johnson & Company Buspirone anti-anxiety method
US4693895A (en) * 1984-10-26 1987-09-15 Alza Corporation Colon delivery system
US4634703A (en) * 1985-10-25 1987-01-06 Bristol-Myers Company Method for alleviation of panic disorders
US4640921A (en) * 1986-02-04 1987-02-03 Bristol-Myers Treatment of sexual dysfunction with buspirone

Also Published As

Publication number Publication date
NZ226604A (en) 1991-07-26
ATE108997T1 (de) 1994-08-15
NO892512L (no) 1989-06-16
ZA887624B (en) 1989-06-28
KR890701087A (ko) 1989-12-19
DK294489D0 (da) 1989-06-15
AU604585B2 (en) 1990-12-20
HK21295A (en) 1995-02-24
DE3850844T2 (de) 1994-12-08
NO892512D0 (no) 1989-06-16
AU2623688A (en) 1989-05-23
YU196488A (en) 1990-04-30
YU47903B (sh) 1996-05-20
FI100303B (fi) 1997-11-14
DK294489A (da) 1989-06-15
EP0313535B1 (en) 1994-07-27
EP0313535A1 (en) 1989-04-26
PT88820B (pt) 1993-01-29
SE8704097D0 (sv) 1987-10-22
JPH02501744A (ja) 1990-06-14
FI893017A (fi) 1989-06-20
IL88020A0 (en) 1989-06-30
DE3850844D1 (de) 1994-09-01
HUT54495A (en) 1991-03-28
IL88020A (en) 1993-08-18
WO1989003676A1 (en) 1989-05-05
KR970004906B1 (ko) 1997-04-08
HU204998B (en) 1992-03-30
HU886266D0 (en) 1991-01-28
JP2674170B2 (ja) 1997-11-12
IE64705B1 (en) 1995-08-23
ES2056955T3 (es) 1994-10-16
IE883177L (en) 1989-04-22
FI893017A0 (fi) 1989-06-20

Similar Documents

Publication Publication Date Title
CA2071408A1 (fr) Comprime matriciel permettant la liberation prolongee d'indapamine apres administration par voie orale
IT1191674B (it) Formulazioni per la preparazione di farmaci a rilascio prolungato adatte alla somministrazione per via orale
DK367687D0 (da) Farmaceutisk praeparat til oral indgift med reguleret afgivelse og forlaenget virkning
GR3019388T3 (en) The use of buspirone for preparing a pharmaceutical composition for the treatment of alcohol abuse
ZA90963B (en) Diphenylheteroalkyl derivatives,the preparation thereof and drugs and cosmetics prepared therefrom
GR3006091T3 (ja)
IL88020A0 (en) Oral formulation of buspirone and salts thereof
NO874850D0 (no) Fremgangsmaate for fremstilling av benzotiadiazinforbindelser og farmasoeytisk akseptable salter derav.
NO171857C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2'-halomethyliden-adenosin-derivater
NO169835C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive katecholkarboksylderivater
EP0351876A3 (en) Composition for potentiating vaccination effect
IL87867A0 (en) Preparation of pharmaceutical compositions containing a 2,6-diamino-pyridine derivatives
MX9203614A (es) Formulacion farmaceutica de liberacion controlada para administracion oral.
PH25180A (en) Formulation for preparing sustained release drugs for oral administration